- Home
- SHBI vs RAPT Comparison
SHBI vs RAPT Comparison
Compare SHBI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHBI | RAPT |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.4M | 498.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHBI | RAPT |
|---|---|---|
| Price | $18.07 | $31.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $18.75 | ★ $57.00 |
| AVG Volume (30 Days) | 183.0K | ★ 406.2K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 38.21 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $212,493,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.77 | N/A |
| P/E Ratio | $10.32 | ★ N/A |
| Revenue Growth | ★ 10.07 | N/A |
| 52 Week Low | $11.47 | $5.67 |
| 52 Week High | $19.22 | $42.39 |
Technical Indicators
Market Signals| Indicator | SHBI | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 45.51 |
| Support Level | $17.37 | $33.01 |
| Resistance Level | $18.00 | $33.24 |
| Average True Range (ATR) | 0.46 | 2.15 |
| MACD | -0.10 | -0.61 |
| Stochastic Oscillator | 45.24 | 20.93 |
Price Performance
Historical ComparisonAbout SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.